ABEO Earnings

ABEO reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 5.25M against an estimate of 5.53M, resulting in a -5.12% surprise. The EPS was -0.1, surpassing the expected -0.27 by 62.96%. The stock experienced a 18.47% price change on the earnings day and a 8.15% change over the next five days, reflecting market reactions to the results.

Following ABEO's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by 18.47% on the day of the release. Over the subsequent five days, it saw a 8.15% change. Historically, ABEO's stock price tends to shift by an average of 2.73% in the 10 days leading up to earnings and 2.47% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ABEO's annual revenue to reach 5.65M, while the EPS is projected at -0.34. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ABEO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ABEO's stock price typically moves by 2.73% in the 10 days before its earnings and 2.47% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.34 and revenue of 5.65M.

The earnings call presents a positive outlook with reduced net loss, progress in market access, and strategic expansion plans. The Q&A section confirms no significant impact on profitability timelines despite delays, maintaining a positive sentiment. The company's progress in securing insurance coverage and expanding treatment centers suggests strong future growth potential. Despite some uncertainties in patient timelines and QTC partnerships, overall sentiment remains positive, supported by optimistic guidance and a clear path to profitability by 2026. The absence of a market cap suggests a neutral to positive reaction, likely around 2% to 8%.